IL313410A - Use of amivantamab to treat colorectal cancer - Google Patents

Use of amivantamab to treat colorectal cancer

Info

Publication number
IL313410A
IL313410A IL313410A IL31341024A IL313410A IL 313410 A IL313410 A IL 313410A IL 313410 A IL313410 A IL 313410A IL 31341024 A IL31341024 A IL 31341024A IL 313410 A IL313410 A IL 313410A
Authority
IL
Israel
Prior art keywords
subject
amibantumab
colon cancer
mcrc
egfr
Prior art date
Application number
IL313410A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL313410A publication Critical patent/IL313410A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL313410A 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer IL313410A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US202163290765P 2021-12-17 2021-12-17
PCT/IB2022/061991 WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Publications (1)

Publication Number Publication Date
IL313410A true IL313410A (en) 2024-08-01

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313410A IL313410A (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Country Status (9)

Country Link
US (2) US20230183360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444426A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500784A (cg-RX-API-DMAC7.html)
KR (1) KR20240112963A (cg-RX-API-DMAC7.html)
AU (1) AU2022407875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241933A1 (cg-RX-API-DMAC7.html)
IL (1) IL313410A (cg-RX-API-DMAC7.html)
MX (1) MX2024007066A (cg-RX-API-DMAC7.html)
WO (1) WO2023105479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
BR112022015140A2 (pt) * 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met

Also Published As

Publication number Publication date
KR20240112963A (ko) 2024-07-19
AU2022407875A1 (en) 2024-07-25
CA3241933A1 (en) 2023-06-15
EP4444426A1 (en) 2024-10-16
MX2024007066A (es) 2024-06-21
US20250257139A1 (en) 2025-08-14
WO2023105479A1 (en) 2023-06-15
JP2025500784A (ja) 2025-01-15
US20230183360A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
Stintzing et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
JP2024153659A5 (cg-RX-API-DMAC7.html)
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
Lilenbaum et al. A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
JP2022521610A5 (cg-RX-API-DMAC7.html)
RU2016148645A (ru) Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого
RU2017136709A (ru) Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr
MX2024007066A (es) Uso de amivantamab para tratar el cancer colorrectal.
JP2023513297A5 (cg-RX-API-DMAC7.html)
MX2021001398A (es) Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
IL278618B1 (en) Cancer treatment
Sartore-Bianchi et al. Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial
JP2025500784A5 (cg-RX-API-DMAC7.html)
Ruff et al. A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer
RU2017142804A (ru) Лечение пациентов с диагнозом аденокарцинома поджелудочной железы с использованием моноклональных антител к рецептору эпидермального фактора роста (egfr)
Yang et al. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study
Sulaiman et al. Comprehensive overview of therapeutic strategies in Colon cancer: Chemotherapy, targeted therapy, and immunotherapy
MY200247A (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
IL308020A (en) Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment
JP2020535180A5 (cg-RX-API-DMAC7.html)
JOP20240049A1 (ar) سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c
JOP20230245A1 (ar) علاج الأورام الخبيثة باستخدام مزيج من الأجسام المضادة لـ pd-1
JP2024509920A5 (cg-RX-API-DMAC7.html)
Augustin ASCO 2025: Driving Knowledge to Action in Cancer Care